Anhui Fengyuan Pharmaceutical Co Ltd (000153) — Strategic Asset Allocation Index
Anhui Fengyuan Pharmaceutical Co Ltd (000153) has a Strategic Asset Allocation Index of 79.1% as of September 2023. Strategic assets (PP&E of CN¥1.49 Billion plus long-term investments of CN¥-) total CN¥1.49 Billion, measured against net assets of CN¥1.89 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check financial resilience of Anhui Fengyuan Pharmaceutical Co Ltd to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Anhui Fengyuan Pharmaceutical Co Ltd Strategic Asset Allocation Index (2000–2022)
This chart shows how Anhui Fengyuan Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 23 annual periods from 2000 to 2022. As of September 2023, the index stands at 79.1%, representing strategic assets of CN¥1.49 Billion against net assets of CN¥1.89 Billion CNY. See Anhui Fengyuan Pharmaceutical Co Ltd (000153) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Anhui Fengyuan Pharmaceutical Co Ltd (2000–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Anhui Fengyuan Pharmaceutical Co Ltd from 2000 to 2022, covering 23 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 000153 market cap.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 83.3% | CN¥1.46 Billion | CN¥1.46 Billion | CN¥- | CN¥1.75 Billion | ▲ +4.7 pp |
| 2021 | 78.5% | CN¥1.22 Billion | CN¥1.22 Billion | CN¥- | CN¥1.56 Billion | ▲ +6.4 pp |
| 2020 | 72.1% | CN¥1.04 Billion | CN¥1.04 Billion | CN¥- | CN¥1.45 Billion | ▲ +6.0 pp |
| 2019 | 66.1% | CN¥877.11 Million | CN¥877.11 Million | CN¥- | CN¥1.33 Billion | ▼ -13.4 pp |
| 2018 | 79.5% | CN¥1.03 Billion | CN¥806.55 Million | CN¥220.26 Million | CN¥1.29 Billion | ▲ +1.8 pp |
| 2017 | 77.7% | CN¥948.62 Million | CN¥817.33 Million | CN¥131.29 Million | CN¥1.22 Billion | ▼ -7.8 pp |
| 2016 | 85.5% | CN¥985.88 Million | CN¥856.21 Million | CN¥129.66 Million | CN¥1.15 Billion | ▼ -0.7 pp |
| 2015 | 86.3% | CN¥1.02 Billion | CN¥913.55 Million | CN¥107.91 Million | CN¥1.18 Billion | ▲ +10.3 pp |
| 2014 | 76.0% | CN¥871.22 Million | CN¥871.22 Million | CN¥- | CN¥1.15 Billion | ▼ -3.9 pp |
| 2013 | 79.8% | CN¥841.75 Million | CN¥841.75 Million | CN¥- | CN¥1.05 Billion | ▼ -14.9 pp |
| 2012 | 94.7% | CN¥734.19 Million | CN¥734.19 Million | CN¥- | CN¥775.01 Million | ▲ +8.0 pp |
| 2011 | 86.7% | CN¥663.57 Million | CN¥663.57 Million | CN¥- | CN¥765.24 Million | ▲ +1.9 pp |
| 2010 | 84.8% | CN¥639.34 Million | CN¥639.34 Million | CN¥- | CN¥753.81 Million | ▲ +1.2 pp |
| 2009 | 83.6% | CN¥567.19 Million | CN¥567.19 Million | CN¥- | CN¥678.70 Million | ▲ +0.6 pp |
| 2008 | 83.0% | CN¥542.99 Million | CN¥542.99 Million | CN¥- | CN¥654.09 Million | ▼ -0.3 pp |
| 2007 | 83.3% | CN¥532.03 Million | CN¥532.03 Million | CN¥- | CN¥638.89 Million | ▲ +3.4 pp |
| 2006 | 79.9% | CN¥495.48 Million | CN¥495.48 Million | CN¥- | CN¥620.49 Million | ▲ +2.7 pp |
| 2005 | 77.2% | CN¥462.59 Million | CN¥462.59 Million | CN¥- | CN¥599.59 Million | ▲ +1.0 pp |
| 2004 | 76.1% | CN¥449.98 Million | CN¥449.98 Million | CN¥- | CN¥591.07 Million | ▼ -1.5 pp |
| 2003 | 77.6% | CN¥447.06 Million | CN¥447.06 Million | CN¥- | CN¥576.00 Million | ▲ +4.8 pp |
| 2002 | 72.8% | CN¥408.47 Million | CN¥408.47 Million | CN¥- | CN¥560.87 Million | ▲ +7.9 pp |
| 2001 | 64.9% | CN¥348.19 Million | CN¥348.19 Million | CN¥- | CN¥536.15 Million | ▲ +33.2 pp |
| 2000 | 31.8% | CN¥169.23 Million | CN¥169.23 Million | CN¥- | CN¥532.50 Million | — |